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Objectives: The aim of this study is to evaluate the cost-effectiveness of Magnetic
Resonance Guided Focused Ultrasound (MRgFUS) compared with alternative treatments
for uterine ﬁbroids in the United States.
Methods: We used techniques of decision analysis and data from secondary sources to
develop and estimate an economic model of the management of uterine ﬁbroids among
premenopausal women. Patients in the model receive treatment with MRgFUS, uterine
artery embolization (UAE), abdominal myomectomy, hysterectomy, or pharmacotherapy.
The model predicts total costs (including subsequent procedures) and quality-adjusted
life-years (QALYs) for each treatment strategy over a lifetime horizon, discounted at
3 percent, from a societal perspective. Data on treatment efﬁcacy and safety were
obtained from published and unpublished studies. Costs (2005 US$) were obtained from
an analysis of a large administrative database and other secondary sources. Lost
productivity costs were included in the base-case analysis, but excluded in a sensitivity
analysis.
Results: UAE was associated with the most QALYs (17.39), followed by MRgFUS
(17.36), myomectomy (17.31), hysterectomy (17.18), and pharmacotherapy (16.70).
Pharmacotherapy was the least costly strategy ($9,200 per patient), followed by
hysterectomy ($19,800), MRgFUS ($27,300), UAE ($28,900), and myomectomy
($35,100). Incremental cost-effectiveness ratios (cost per QALY gained) were $21,800 for
hysterectomy, $41,400 for MRgFUS, and $54,200 for UAE; myomectomy was more costly
and less effective than both MRgFUS and UAE. Results were sensitive to MRgFUS
recurrence rates, MRgFUS procedure costs, and assumptions about quality of life
following hysterectomy.
Conclusions: Our ﬁndings suggest that MRgFUS is in the range of currently accepted
criteria for cost-effectiveness, along with hysterectomy and UAE.
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Uterine ﬁbroids, or leiomyomas, are the most common be-
nign tumors in women of childbearing age (42). Approxi-
mately 25 percent of women with ﬁbroids experience symp-
toms such as heavy bleeding, pelvic pain, and pregnancy
complications (7). In addition to the clinical burden, the eco-
nomic burden of ﬁbroids is also substantial; the total direct
cost of uterine ﬁbroids in the United States was recently
estimated to be $2.2 billion annually (15).
Although medications such as nonsteroidal anti-
inﬂammatorydrugs(NSAIDs)and/orhormonaltherapymay
be used to manage ﬁbroid symptoms, some women require
more aggressive forms of treatment. Historically, the most
common treatment for ﬁbroids has been hysterectomy; al-
ternative options include myomectomy or uterine artery em-
bolization (UAE). Each of these options has its advantages
and disadvantages. For example, while hysterectomy elim-
inates symptoms permanently, it is associated with risks of
surgicalcomplications,lengthyrecoverytimes,missedwork,
and potentially negative quality-of-life outcomes associated
with the loss of the uterus (5). Hysterectomy is also not
appropriate for women who desire future childbearing. My-
omectomy is often the treatment of choice for women who
want to preserve fertility, but it is not completely effective in
eliminatingsymptoms(29;37)andisassociatedwithsurgical
risks (2). UAE has a lower rate of major complications than
hysterectomy or myomectomy, but a higher rate of minor
complications, and is associated with more urgent visits and
rehospitalizations (19), and is not approved for women who
desire future fertility.
Magnetic Resonance Guided Focused Ultrasound
(MRgFUS) is a minimally invasive procedure that uses ul-
trasound as the treatment modality and magnetic resonance
to provide guidance and real time feedback. MRgFUS has
received FDA approval for the treatment of uterine ﬁbroids
for women who no longer desired fertility, and authors of
published studies report that MRgFUS is a safe and effective
treatment for ﬁbroids (14;30;35;36).
Treatment choice depends not only on the ﬁbroids’
size and location, but also on patient preference, qual-
ity of life implications, and cost. Several economic stud-
ies of uterine ﬁbroid treatments have been published
(1;4;5;10;18;24;26;43),butnostudytodatehasexaminedthe
cost-effectiveness of MRgFUS relative to each of the other
treatmentoptionsavailableintheUnitedStates.Accordingly,
we conducted a cost-effectiveness analysis of MRgFUS rela-
tivetohysterectomy,myomectomy,UAE,andpharmacother-
apyinthetreatmentofuterineﬁbroidsamongpremenopausal
women in the United States.
METHODS
Model Overview
WedevelopedaMarkovmodeltoestimatethelong-termout-
comes and costs among a cohort of premenopausal women
receiving treatment for symptomatic uterine ﬁbroids. The
model assumes that women are offered ﬁrst-line treatment
with hysterectomy, myomectomy, UAE, MRgFUS, or pain
management with pharmacotherapy only. The model is com-
prised of health states deﬁned by presence/absence of symp-
toms and treatment received, with transitions across health
states occurring at 6-month intervals. Each health state is
associated with a utility and an economic cost. Estimation
of the model involves tracking patients’ transitions across
health states over time and tabulating their quality-adjusted
life-years (QALYs) and costs until death.
With the exception of the pharmacotherapy arm, all pa-
tientsenteringthemodelundergoroutinediagnostictestsbe-
foretheprocedure(Figure1a).WomeninitiatedwithUAEor
MRgFUS are assumed to undergo additional imaging tests
to assess eligibility (9), as a proportion of women in each
group will not be eligible due to the size and location of
ﬁbroids. Those who are determined to be ineligible for UAE
or MRgFUS receive an alternative procedure. All women are
assumedtobeeligibleforhysterectomyandmyomectomy.
Patients in the model are at risk for procedure-related
complications or death (Figure 1b). Those who survive will
either experience symptom relief or have treatment failure;
those who fail are assumed a priori to receive second-line
treatment with an alternative procedure. Women who are
successfully treated are at risk of symptom recurrence until
they reach menopause. In the model, women can receive a
maximum of three rounds of treatment due to treatment fail-
ure or symptom recurrence. Third-line treatment is assumed
to be hysterectomy in all cases, which completely eliminates
the ﬁbroids.
Patients initiated in the model are assumed to be pre-
menopausal women (mean age, 40 years) with previously
untreated symptomatic ﬁbroids. In base-case analyses, we
estimated total costs (in 2005 dollars), QALYs, and cost-per-
QALYgainedfromasocietalperspective,includinglostpro-
ductivity costs and effects on quality of life. We evaluated an
alternative scenario in which productivity costs were omit-
ted, according to the Reference Case recommendations of
the U.S. Panel on Cost-Effectiveness in Health and Medicine
(17).
Treatment of Uterine Fibroids
Withtheexceptionofhysterectomy,notreatmentcompletely
eliminates uterine ﬁbroids. Consequently, many women re-
quire follow-up treatment to achieve symptom resolution
(33;37).Unfortunately,weareunawareofanypublisheddata
on retreatment patterns (e.g., the distribution of second-line
treatments received among women who fail ﬁrst-line treat-
ment). Furthermore, there are no published data on treatment
patternsamongwomenwhoareclinicallyineligibleforUAE
or MRgFUS.
Giventheabsenceofpublisheddata,wemadeseveralas-
sumptions regarding treatment patterns among women with
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Figure 1a. Screening and eligibility for treatments for uterine ﬁbroids.
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Figure 1b. Outcomes associated with treatments for uterine ﬁbroids.
uterine ﬁbroids. First, we assumed that nearly all women
who are determined to be ineligible for either MRgFUS or
UAE would prefer the least invasive of the remaining treat-
ment options (excluding pharmacotherapy). Second, based
on the premise that women seeking treatment desire com-
plete elimination of symptoms, we assumed that once a pa-
tient undergoes a procedure, she continues to be treated until
her symptoms have resolved. If a patient fails ﬁrst-line treat-
ment, it is assumed that she receives second-line treatment
with one of the more invasive strategies (based on treatment
patterns estimated from a large administrative database). Pa-
tients who experience symptom recurrence are assumed to
be retreated with the ﬁrst-line strategy. All patients requir-
ing a third-line strategy—whether for second-line failure or
symptom recurrence—are assumed to receive hysterectomy.
Finally, we assumed that pharmacotherapy was used only in
instances in which the patient did not want to undergo an
invasive procedure; consequently no further treatment was
modeled for this strategy.
Model Parameters and Data Sources
Model parameters and corresponding data sources are sum-
marized in Table 1 and described below.
Treatment Eligibility. The proportion of women el-
igible for MRgFUS was estimated based on data from In-
Sightec (Tirat Carmel, Isreal). Eligibility for UAE was es-
timated based on expert opinion (E.A.S.). It was assumed
that all women are eligible for treatment with hysterectomy,
myomectomy, or pharmacotherapy.
Treatment Efﬁcacy. We estimated the proportions of
women experiencing symptom relief and recurrence with
hysterectomy(6),myomectomy(1),andUAE(6;27;32)from
Technology Assessment Reports and published studies. The
efﬁcacy of MRgFUS was estimated from unpublished clini-
cal trial data (22). We used data from a subgroup of patients
treated according to a set of “expanded” guidelines, as these
guidelines closely resemble the commercial guidelines ap-
proved for MRgFUS in 2004.
Due to a scarcity of data on recurrence rates following
treatment of uterine ﬁbroids, we used retreatment rates to
proxy for recurrence. We reviewed studies of various follow-
up times and standardized all retreatment rates to 6-month
risks using an exponential failure time model. In the model,
we assumed a constant risk of recurrence in every cycle until
menopause.
Thelikelihoodofrecurrencewithhysterectomy(6),my-
omectomy (37), and UAE (33) were estimated from pub-
lished studies. Recurrence with MRgFUS was based on re-
treatment rates from the same trial from which efﬁcacy data
were obtained (22). Probabilities of symptom relief and re-
currence with each strategy were assumed to be the same re-
gardless of whether the procedure served as a ﬁrst-, second-,
or third-line strategy.
Treatment Safety. ConsistentwithBeinfeldetal.(5),
we obtained the rates of major complications and procedure-
related death with hysterectomy from a large prospective
study (11). Rates of major complications and procedure-
related death for myomectomy were assumed to be equal to
those for hysterectomy, based data from two studies (13;23).
The risks of major complications (32) and procedure-related
death (31) for UAE were obtained from published studies.
Rates of major complications and death for MRgFUS were
obtained from trial data (14;21).
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Table 1. Model parameters, base-case estimates, and data sources
Model Parameter Estimate Data Source
Treatment Eligibility
Proportion eligible for treatment
Hysterectomy 100% Expert opinion
Myomectomy 100% Expert opinion
UAE 90% Expert opinion
MRgFUS 35% Data on ﬁle, Insightec
Pain management 100% Assumption
Treatment Efﬁcacy∗
Probability of symptom relief
Hysterectomy 100% BCBS Technology Assessment Program 2002
Myomectomy 90% AHRQ Report No. 34, 2001
UAE 90% Pelage 2000; Beinfeld 2004
MRgFUS 92% Unpublished data from Insightec, Clinical trial UF005
Probability of recurrence in a 6-month period
Hysterectomy 0% Assumption
Myomectomy 5% Subramanian 2001
UAE 3% Spies 2005
MRgFUS 6% Unpublished data from Insightec, Clinical trial UF005
Treatment Safety∗
Probability of major complications
Hysterectomy 2.0% Dicker 1982; Beinfeld 2004
Myomectomy 2.0% Ecker 1995; Iverson 1996
UAE 0.5% Spies 2001; Beinfeld 2004
MRgFUS 0% Unpublished data from Insightec, Clinical trial UF005
Probability of procedure-related death
Hysterectomy 0.2% Dicker 1982; Beinfeld 2004
Myomectomy 0.2% Assumption
UAE 0.15% Smith 2001; Beinfeld 2004
MRgFUS 0.0% Unpublished data from Insightec, Clinical trial UF005
Medical-Care Costs†
Screening costs
Hysterectomy $207 Expert opinion, Medicare RBRVS
Myomectomy $207 Expert opinion, Medicare RBRVS
UAE $826 Expert opinion, Medicare RBRVS
MRgFUS $826 Expert opinion, Medicare RBRVS
Procedure-related costs
Hysterectomy $10,155 Medstat database analysis, data on ﬁle GE Healthcare
Myomectomy $9,419 Medstat database analysis, data on ﬁle GE Healthcare
UAE $11,341 Medstat database analysis, data on ﬁle GE Healthcare
MRgFUS $6,768 Unpublished data, Insightec
Annual cost of care for pharmacotherapy strategy $945 Expert opinion, Medicare RBRVS
Costs for estrogen-only hormone replacement
therapy (per month)
$36.90 Red Book 2005
Monitoring costs for successfully treated women
(per year)
$47.70 Expert opinion, Medicare RBRVS
Lost Productivity Costs
Total days of missed work due to procedure
Hysterectomy 39.8 Medstat database analysis, data on ﬁle GE Healthcare
Myomectomy 38.9 Medstat database analysis, data on ﬁle GE Healthcare
UAE 11.6 Medstat database analysis, data on ﬁle GE Healthcare
MRgFUS 2.0 Assumption
Daily wage rate for women $184.00 Bureau of Labor Statistics Usual Weekly Earnings of
Wage and Salary Workers: First quarter, 2006
Utilities
Symptomatic ﬁbroids 0.67 Unpublished data from Insightec, Clinicial trial UF 008
Symptomatic relief 0.76 Unpublished data from Insightec, Clinicial trial UF 008
Death 0.00 Deﬁnition
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Table 1. Continued.
Percent reduction in utility during recovery from
hysterectomy
20.0% Assumption
Percent reduction in utility associated with major
complications
20.0% Assumption
Percent reduction in utility post-hysterectomy 1.5% Assumption
Discount rate 3.0% Assumption
∗Efﬁcacy and safety with second- and third-line treatment are assumed to be the same as for the corresponding ﬁrst-line treatment.
†Costs are in 2005 US dollars. Screening for all procedures is assumed to require 2 ofﬁce visits, an ultrasound, and lab tests; screening for UAE and
MRgFUS also requires an MRI. Costs for treating complications are included in procedure costs. Costs for the pharmacotherapy strategy include
those for 4 ofﬁce visits, 2 ultrasounds, and pain medication.
Medical-Care Costs. Costs (in 2005 US$) associ-
ated with treatment of uterine ﬁbroids are comprised of di-
rect medical as well as lost productivity costs. Medical-care
costs include those for preprocedure screening tests, the pro-
cedure, procedure-related complications, medications, and
postprocedure monitoring.
Routine screening for all procedures was assumed to
require two ofﬁce visits (one each for CPT code 99212 and
99213), an ultrasound (CPT code 76856), and lab tests (i.e.,
complete blood count and urine pregnancy test). In addition,
screening for UAE and MRgFUS was assumed to require an
MRI (CPT code 72196).
Procedure costs for hysterectomy, myomectomy, and
UAE were derived from a large, retrospective study of com-
mercially insured women (8). Costs included payments from
all inpatient, outpatient, and prescription drug claims on the
day(s) spent in hospital for the procedure. Costs for inpatient
procedures included those for all services rendered during
the hospital stay, and, therefore, included costs for treating
procedure-related complications. The cost for MRgFUS was
obtained from InSightec, and includes costs of the follow-
ing: the ExAblate 2000 R   device used to perform MRgFUS
(assuming a 60-month lease and routine maintenance); MRI
time; physician (radiologist and surgeon), nursing, and tech-
nician time (including hourly wage plus fringe beneﬁts); pa-
tient sedation; and recovery room.
Women who are managed with pharmacotherapy alone
are assumed to require four ofﬁce visits, two ultrasounds,
and two complete blood tests annually. Medication costs for
analgesicsandhormonetherapywereobtainedfromareview
of the economic burden of uterine ﬁbroids (24) and weighted
by the distribution of women who are managed with each
strategy as reported in the Thomson Medstat database (8).
We assumed that a proportion of women (20 percent)
who receive a hysterectomy also receive estrogen-only hor-
mone replacement therapy following surgery. Drug acquisi-
tioncostsforthesetherapieswereestimatedbasedonaverage
wholesale prices (12). Finally, women who are successfully
treated for their ﬁbroids were assumed to receive one physi-
cian visit and one ultrasound annually.
Lost Productivity Costs. Costs due to lost produc-
tivity were estimated by multiplying the work days missed
due to the procedure and recovery by the loaded daily wage
rate. Days missed due to procedure and recovery for hys-
terectomy, myomectomy, and UAE were obtained from a
study by Carls and colleagues (8). Days missed for MRg-
FUS were estimated based on data from early trials (21;30).
We estimated the daily wage rate using data from the U.S.
Bureau of Labor Statistics on the median weekly earnings
for women aged 35 to 54 years in the United States (40).
Health-Related Quality of Life. Utility values for
women with symptomatic ﬁbroids and symptom relief were
obtained from a clinical trial of MRgFUS (22). Consistent
withBeinfeldetal.(5),weassumedthatpatientswhoreceive
a hysterectomy are subject to a 0.20 decrement in utility for
the6-monthperiodfollowingtheproceduretoaccountforre-
duced quality of life during the recovery period; women who
experiencehysterectomy-relatedcomplicationsaresubjectto
an additional 0.20 decrement. Finally, women who receive
a hysterectomy are assumed to have a 0.015 decrement in
quality of life for the remainder of their lives to account for
the long-term effects of hysterectomy on a woman’s quality
of life.
Discount Rate. All costs and QALYs were dis-
countedtothebeginningofthemodelperiodusinga3percent
annual discount rate.
Analyses
Base-Case Analyses. Cumulative costs (including
those for lost productivity) and QALYs were calculated from
initial screening until death, and were used to estimate the
incremental cost-per-QALY gained for each of the compara-
tors. Incremental cost-effectiveness ratios were estimated by
rank-ordering the treatment regimens by increasing cost and
then comparing the more costly to the next-most costly strat-
egy by dividing the additional cost by the additional beneﬁt.
Dominated treatment strategies, including those that were
more costly and less effective than an alternative (“strong
dominance”) and those that had a less favorable incremen-
tal cost-effectiveness ratio than a more expensive alternative
(“extendeddominance”)wereeliminatedfromtheincremen-
tal cost-effectiveness analysis using conventional methods
(17). Base-case analyses were performed from a societal
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Figure 2. Total costs by component per patient receiving alternative uterine ﬁbroid treatments.
perspective, including costs of lost productivity and all ef-
fects on quality of life.
Sensitivity Analyses. To assess uncertainty in the
base-case results, we conducted one-way sensitivity analy-
ses by varying key model parameters one at a time through
plausiblerangesandexaminingtheeffectsontheincremental
cost-effectiveness ratios. As in the base-case analysis, pro-
ductivity costs were included in total cost estimates. In each
one-way sensitivity analysis we identiﬁed which of the com-
peting strategies would be the most cost-effective at thresh-
olds of $50,000 or $100,000 per QALY gained.
Reference Case Analysis. In addition to the base
case, we performed a Reference Case analysis as deﬁned by
the U.S. Panel on Cost-Effectiveness in Health and Medicine
(17). The Panel recommends omitting the costs of lost pro-
ductivity from the numerator of the cost-effectiveness ratio,
under the assumption that effects on productivity are cap-
tured in the utility weights in the denominator. Therefore, in
the Reference Case analysis we excluded these costs.
Alternative Analyses. Due to the paucity of data on
theefﬁcacyandsafetyoftreatmentforuterineﬁbroids,inad-
ditiontoone-waysensitivityanalysesweconductedavariety
of alternative analyses in which we varied one or more pa-
rameters according to less conservative estimates than those
usedinthebasecase.Asratesofcomplicationswithhysterec-
tomy, myomectomy, and UAE vary widely in the literature,
in the ﬁrst alternative analysis we assumed that the rates of
complications after hysterectomy, myomectomy, and UAE
are equal to those used in a UK cost-effectiveness study of
MRgFUS (43) (i.e, 6.2 percent for hysterectomy and my-
omectomy and 4 percent for UAE). In addition, in the same
analysis we assumed that there exist complication costs for
these procedures that are not included in our base-case pro-
cedure cost (i.e., assuming that the complications occur after
discharge). As costs of complications associated with these
procedures are scarce in the literature, for the purposes of
this alternative analysis we assumed that the costs of com-
plications occurring postdischarge are equal to 50 percent of
the procedure cost.
In the second alternative analysis, we assumed a recur-
rence rate for MRgFUS of 3.6 percent. This is equal to the
weighed average of recurrence rates used in the study by
Zowall et al. (43). Zowall et al. used recurrence rates of 0.8
percent in the ﬁrst 6 months, 6.49 percent in 6–12 months
and 3.63 percent in 12–24 months based on pooled data from
a selected group of patients (those with the nonperfused vol-
ume relative to total ﬁbroids volume of 60 percent) from four
clinical trials of MRgFUS.
In the third alternative analysis, we vary the eligibility
rate for MRgFUS to 50 percent and 90 percent, under the as-
sumptionthattheproportionofpatientseligiblewillincrease
in future years as the procedure is more widely incorporated
into clinical practice.
RESULTS
Base-Case Results
Lifetime discounted total costs (including lost productiv-
ity) per patient were lowest for the pharmacotherapy strat-
egy at $9,200. Among the procedures, hysterectomy was
the least costly ($19,800), followed by MRgFUS ($27,300),
UAE ($28,900), and myomectomy ($35,100). The propor-
tions of total costs attributable to screening, the procedure,
lost productivity, and other costs varied by treatment strat-
egy (Figure 2). For example, procedure costs were highest
for UAE, comprising over 68 percent of the total costs for
that strategy, while hysterectomy and myomectomy had the
largest proportions of total costs attributable to lost produc-
tivity (37 percent and 41 percent, respectively). Productivity
costs for myomectomy are higher than those for hysterec-
tomy because it results in the most follow-up procedures. In
themodel,myomectomypatientswhofailedinitialtreatment
were assumed to undergo a hysterectomy, thus these patients
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Table 2. Cost-effectiveness of treatments for uterine ﬁbroids.
Treatment Strategy Total Cost∗ Incremental Cost Total QALYs∗ QALYs Gained ICER (Cost per QALY)
Pharmacotherapy $9,207 – 16.699 – –
Hysterectomy $19,799 $10,592 17.183 0.485 $21,800
MRgFUS $27,285 $7,486 17.364 0.181 $41,400
UAE $28,892 $1,607 17.394 0.030 $54,200
Myomectomy $35,057 – 17.305 – Strongly dominated†
∗per patient, discounted at 3.0%
†‘Strongly dominated’ meaning the strategy is both more costly and less effective than a more effective strategy
incurred productivity losses due to myomectomy as well as
hysterectomy. In contrast, hysterectomy is assumed to be
100 percent effective, so none of the hysterectomy patients
required subsequent treatment.
Under base-case assumptions, treatment with UAE was
associated with the most discounted QALYs (17.39), fol-
lowed by MRgFUS (17.36), myomectomy (17.31), hys-
terectomy (17.18), and pharmacotherapy (16.70). The incre-
mental cost-effectiveness ratios, or costs-per-QALY gained,
were $21,800 for hysterectomy (relative to pharmacother-
apy), $41,400 for MRgFUS (relative to hysterectomy), and
$54,200 for UAE (relative to MRgFUS) (Table 2). Myomec-
tomy was strongly dominated, meaning that it was more
costly than at least one more effective strategy.
One-Way Sensitivity Analyses
Results of the one-way sensitivity analysis are shown in
Table 3. Model parameters were varied across plausible
ranges and the strategies that would be cost-effective at
willingness-to-pay thresholds of $50,000 and $100,000 per
QALY gained, alternatively, were identiﬁed. Note that the
strategy that is most cost-effective at a speciﬁed threshold is
not necessarily the one with the lowest ratio, but rather the
one with a ratio that comes closest to the threshold without
exceeding it. For example, in the base case, if a payer’s will-
ingnesstopayis$50,000perQALYgained,thecost-effective
strategy would not be hysterectomy ($21,800 per QALY
gained), but MRgFUS ($41,400 per QALY gained), as this
is the alternative that would provide the greatest beneﬁt at an
incremental cost-effectiveness ratio not exceeding the speci-
ﬁedcriterionof$50,000perQALYgained.AsUAE($54,200
perQALYgained)hasanincrementalcost-effectivenessratio
relative to MRgFUS that comes closest to a $100,000 thresh-
old without going over it, it would be the treatment of choice
for a payer with a threshold of $100,000 per QALY gained.
The cost-effectiveness ratios and the most cost-effective
treatment choices at the speciﬁed thresholds were most sen-
sitive to the probability of symptom relief, the probability
of symptom recurrence, and procedure costs for UAE and
MRgFUS. For example, when the probability of recurrence
with UAE is varied from its low (2 percent) to its high
(5 percent) value (base case = 3 percent), its incremental
cost-effectiveness ratio ranges from $26,100 to $317,300 per
QALY gained relative to MRgFUS. Therefore, at a cost-per-
QALY threshold of $50,000 per QALY, UAE would be cost-
effectiveifitsrecurrenceratewasatthelowendoftherange,
whereas MRgFUS was cost-effective based on this threshold
in the base case. At the high end of the range of UAE recur-
rence rates, hysterectomy becomes cost-effective; because
UAE is the second-line treatment for MRgFUS, factors that
make UAE less attractive also adversely affect the MRgFUS
strategy.IfMRgFUShadarecurrencerateaslowas3percent
(base case = 6 percent), the incremental cost-effectiveness
ratios for MRgFUS (vs. hysterectomy) and UAE (vs. MRg-
FUS) would be $28,700 and $603,000 per QALY gained
respectively. Alternatively, at a threshold of 7 percent recur-
rence, MRgFUS becomes dominated by UAE. The lifetime
utility decrement associated with hysterectomy also has a
substantial impact on the cost-effectiveness ratios. When the
decrement is varied from 0.0 to 0.025 (base case = 0.015),
MRgFUS ranges from being dominated by hysterectomy to
having an incremental cost-per-QALY gained of $30,100.
Results were fairly insensitive to variations in model param-
eters not contained in Table 3.
Reference Case Analysis
In the Reference Case analysis, productivity losses are as-
sumed to be reﬂected in the utility estimates (and, there-
fore, omitted from the cost estimates). In this case, myomec-
tomy remains strongly dominated, and the conclusions from
the cost-effectiveness analysis are similar to base case. The
incremental cost-effectiveness ratios are $6,700 per QALY
gainedforhysterectomy,$45,000forMRgFUS,and$58,000
for UAE.
Alternative Analyses
Due to the wide-ranging estimates of rates and costs of com-
plications associated with hysterectomy, myomectomy, and
UAE in the literature, in the ﬁrst alternative analysis we
assumed that the rates of complications with hysterectomy
and myomectomy are each 6.2 percent, and the complication
rate with UAE is equal 4 percent. In addition, we assumed
additional costs of these complications equal to 50 percent
of the procedure cost. Under these assumptions, the incre-
mental cost-effectiveness ratio for hysterectomy relative to
pharmacotherapy is $32,500 per QALY gained, the ratio for
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Table 3. The impact of variation in model parameters on the incremental cost-effectiveness of MRgFUS.
Cost-effective strategy when the willingness-to-pay
threshold is:
Parameter Value $50,000/QALY gained $100,000/QALY gained
Probability of symptom relief, myomectomy (base-case) 90% MRgFUS UAE
Low 80% MRgFUS UAE
High 100% MRgFUS UAE
Probability of symptom relief, UAE (base-case) 90% MRgFUS UAE
Low 80% Hysterectomy UAE
High 100% UAE UAE
Probability of symptom relief, MRgFUS (base-case) 92% MRgFUS UAE
Low 80% UAE UAE
High 100% MRgFUS UAE
Probability of recurrence, myomectomy§ (base-case) 5% MRgFUS UAE
Low 3% MRgFUS UAE
High 8% UAE UAE
Probability of recurrence, UAE§ (base-case) 3% MRgFUS UAE
Low 2% UAE UAE
High 5% Hysterectomy MRgFUS
Probability of recurrence, MRgFUS§ (base-case) 6% MRgFUS UAE
Low 3% MRgFUS MRgFUS
High 10% UAE UAE
Procedure-related costs, hysterectomy (base-case) $10,155 MRgFUS UAE
Low $7,600 MRgFUS UAE
High $12,700 UAE UAE
Procedure-related costs, myomectomy (base-case) $9,419 MRgFUS UAE
Low $7,000 MRgFUS UAE
High $11,800 UAE UAE
Procedure-related costs, UAE (base-case) $11,341 MRgFUS UAE
Low $8,500 UAE UAE
High $14,200 Hysterectomy MRgFUS
Procedure-related costs, MRgFUS (base-case) $6,768 MRgFUS UAE
Low $5,100 MRgFUS UAE
High $8,500 UAE UAE
Utilities
Symptomatic ﬁbroids †§ (base-case) 0.67 MRgFUS UAE
Low 0.50 Hysterectomy UAE
High 0.78 UAE UAE
Symptomatic relief †§ (base-case) 0.76 MRgFUS UAE
Low 0.60 Hysterectomy UAE
High 0.90 UAE UAE
Percent reduction in utility during recovery from
hysterectomy (base-case)
20.0% MRgFUS UAE
Low 0.0% Hysterectomy UAE
High 25.0% MRgFUS UAE
Percent reduction in utility associated with major
complications (base-case)
20.0% MRgFUS UAE
Low 0.0% MRgFUS UAE
High 25.0% MRgFUS UAE
Percent reduction in utility post-hysterectomy (base-case) 1.5% MRgFUS UAE
Low 0.0% Hysterectomy Hysterectomy
High 2.5% UAE UAE
Discount rate (base-case) 3.0% MRgFUS UAE
Low 0.0% UAE UAE
High 5.0% MRgFUS UAE
Ranges estimated based on reasonable estimates of model values unless otherwise noted
§Range for parameter based on literature
†High and low ranges for utilities for symptomatic ﬁbroids and symptomatic relief moved together
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MRgFUS relative to hysterectomy is $55,800 per QALY
gained, and the ratio for UAE relative to MRgFUS is
$133,600 per QALY gained. As in the base case, myomec-
tomy is dominated due to the fact that it is more costly and
less effective than at least one other alternative.
Ifthe6-monthrecurrenceratewithMRgFUSisassumed
to be 3.6 percent, the incremental cost-effectiveness ratio
for hysterectomy relative to pharmacotherapy is $21,800 per
QALY gained, the ratio for MRgFUS relative to hysterec-
tomy is $31,600 per QALY gained, and the ratio for UAE
relative to MRgFUS is $248,000 per QALY gained. Again,
myomectomy is a dominated alternative.
In the third alternative analysis, we vary the eligibility
rate for MRgFUS to 50 percent and 90 percent. Should the
eligibility rate with MRgFUS increase to 50 percent (from
a base case of 35 percent), the cost per QALY gained for
hysterectomy relative to pharmacotherapy is $21,800, the
cost per QALY gained forMRgFUS relative tohysterectomy
is $38,700, and the cost per QALY gained for UAE relative
to MRgFUS is $64,300. Corresponding ﬁgures under the
90 percent eligibility assumption are $21,800, $30,100, and
$78,400 per QALY gained. Under both alternative scenarios
regarding eligibility, myomectomy remains dominated.
DISCUSSION
Our results suggest that MRgFUS is in the range of currently
accepted criteria for cost-effectiveness, along with hysterec-
tomy and UAE. Myomectomy was both more costly and less
effective than MRgFUS and UAE. In the base-case analy-
sis, incremental cost-effectiveness ratios were $21,800 per
QALY gained for hysterectomy, $41,400 for MRgFUS, and
$54,200 for UAE. Results are sensitive to changes in rates
of ﬁbroid recurrence with the different treatments, proce-
dure costs, eligibility rate with MRgFUS, and assumptions
regarding quality-of-life following hysterectomy.
Very few studies of the cost-effectiveness of uterine ﬁ-
broidstreatmentexist,likelydueinparttothescarcityofdata
on efﬁcacy and safety of these procedures (1). Beinfeld and
colleagues (5) compared the cost-effectiveness of UAE with
hysterectomy and reported that UAE is cheaper and more
effective than hysterectomy. In contrast, our results indicate
that UAE is more costly and more effective (as measured by
QALYs gained) relative to hysterectomy. Unlike Beinfeld et
al., we included screening costs, treatment eligibility crite-
ria, and multiple rounds of follow-up treatment for failure
or recurrence. These components likely caused the average
cost of UAE to be higher than hysterectomy in our analysis
relative to Beinfeld.
The Agency for Healthcare Research and Quality com-
pared costs and outcomes of hysterectomy and myomec-
tomy, and concluded that hysterectomy results in favorable
outcomes for up to 2 years (1). However, researchers con-
cluded that there were insufﬁcient data for a head-to-head
comparison, and thus gave no recommendations for the most
appropriate treatment strategy.
Mostrecently,Zowallandcolleaguesestimatedthecost-
effectiveness analysis of MRgFUS versus a “current prac-
tice” strategy (distribution of UAE, myomectomy, and hys-
terectomy) from the perspective of the National Health Ser-
vice (NHS) in the UK (43). They report that MRgFUS is
associated with cost savings and a small QALY gain relative
to current practice. Our model differs from theirs in several
majorways.First,whileZowall’smodelfollowswomenuntil
they reach menopause, ours is a lifetime model and includes
physician monitoring costs and effects on quality-of-life that
persist over a woman’s lifetime. Notable among these life-
long effects in our model is the quality-of-life decrement
attributable to having had hysterectomy. Second, in contrast
to Zowall, we included costs of screening tests to determine
eligibility (as they vary by treatment strategy); we also ac-
counted for the fact that not everyone who is screened for
UAEorMRgFUSiseligibletoreceivetheprocedure.Infact,
manywomenwhoareinitiatedwithUAEorMRgFUSendup
receiving a different procedure altogether. The differences in
relative prices for the various procedures is a third important
factor.Forexample,thecostofhysterectomyintheUKstudy
wasestimatedat£2,727(approximately$5,500atcurrentex-
changerates),whileweestimatedthecostofhysterectomyin
the United States to be $10,155, and assumed that all women
who failed two lines of treatment received a hysterectomy.
A fourth difference from Zowall et al. is that we used recur-
rence rates for MRgFUS derived from the full clinical trial
population,whereastheyrestrictedtheirestimatestothesub-
set of patients for whom the nonperfused ﬁbroid volume was
60 percent or more of the total. In an alternative analyses
in which we used their recurrence assumptions, the quali-
tative result that MRgFUS was cost-effective at a criterion
of $50,000 per QALY was unchanged, but MRgFUS also
became cost-effective at a criterion of $100,000 per QALY
(because the incremental ratio for UAE compared to MRg-
FUS roseto $248,000 per QALY.) Finally, Zowall et al. com-
pared MRgFUS to a single strategy that assumes 25 percent
of women receive UAE, 25 percent receive myomectomy,
and 50 percent receive hysterectomy. Our model includes a
separate comparison with each of these strategies, to reﬂect
the different outcomes and costs associated with each. The
fact that the comparator to MRgFUS in the Zowall study is
a composite that includes myomectomy (strongly dominated
according to our model) is likely a large contributing factor
to the differences between our results and those of Zowall
et al.
Someimportantlimitationsofourstudyshouldbenoted.
Any cost-effectiveness study is subject to the limitations sur-
rounding uncertainty in key model parameters. Because one-
way sensitivity analyses revealed that the cost-effectiveness
of three treatment options was very sensitive to several pa-
rametersandassumptions,wedidnotconductaformalprob-
abilistic sensitivity analysis. Such an analysis would have
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reinforced our conclusion that the current choice of treat-
ment could easily go any of three different ways.
We assumed that 35 percent of women who present for
treatment with MRgFUS will be clinically eligible to receive
the procedure. While a recent study reported that 14 percent
ofwomeninquiringaboutparticipatinginatrialofMRgFUS
were eligible for the procedure, the authors acknowledged
that their ﬁndings are likely to be lower than the reality due
to restrictions imposed by their institution’s Committee for
Human Rights and the FDA (3). They conclude that once the
procedure is used in clinical practice, eligibility rates will be
higher. Our estimate is based on clinical input and communi-
cation from participating sites. We believe that the eligibility
rate will increase as physicians become more comfortable
with the technology and it is more widely assimilated into
clinical practice.
Estimation of the probability of symptom relief with ﬁ-
broid treatments posed some difﬁculty due to the scarcity
of randomized controlled trials on ﬁbroid treatments, mea-
surement differences across studies, and varying lengths of
follow-up. Estimating recurrence rates is also challenging.
Recurrence can be deﬁned in terms of symptoms or alterna-
tively in terms of re-growth; due to the inconsistency in deﬁ-
nitions, we used rates of retreatment to proxy for recurrence.
We reviewed studies that reported retreatment rates regard-
less of the speciﬁc procedure (e.g., hysterectomy, myomec-
tomy) received, standardized rates to 6-month risks using an
exponential failure time model, and assumed a constant risk
of recurrence in every 6-month period until menopause in
the model. While recurrence is unlikely to be constant over
time, at present no long-term data are available to contradict
our assumption.
Quantitative data on the short- and long-term impact of
hysterectomy on quality of life also are limited. With respect
to short-term effects, we followed Beinfeld et al. (5), and
assumed a 0.20 reduction in the utility in the cycle in which
complicationsoccuraswellasa0.20reductionduringrecov-
ery from hysterectomy. Regarding long-term effects, while
somestudiessuggestthatwomenexperienceanimprovement
in their quality of life following hysterectomy due to the fact
that the condition for which they sought treatment is gone
(28;34), other studies cite long-term negative effects such
as an increase in cardiovascular risk, mental health issues,
sexual problems, incontinence, and vaginal vault prolapse
(20;39;41). We did not account for an increase in cardio-
vascular disease risk among women who had hysterectomy,
as this is controversial and the quantitative impact is unclear.
However,wealsoexcludedthereductionintheriskofuterine
cancer, so we believe that any bias from excluding long-term
risks is small. In our model, the quality of life improvement
due to elimination of ﬁbroid symptoms following hysterec-
tomy is captured in the health-state utility weights; long-
term reductions in quality of life is captured by a lifetime
decrement of 0.015 for women who received a hysterec-
tomy. While we found similar estimates for quality of life
decrements associated with comparable chronic conditions
(38), data to support the long-term effects of hysterectomy
on quality of life would strengthen our conclusions.
Our analysis does not include the impact of treatment
on childbearing choices. Myomectomy is the only proce-
dure currently recommended for women who desire future
fertility.AlthoughMRgFUSistheleastinvasiveoftheproce-
dures studied here and there exist case studies of successful
pregnancies among women who have received it (16;25),
MRgFUS is currently limited in its indication for use among
women who do not desire future fertility. As the choice of
treatment depends not only on cost and effectiveness but also
on patient preferences, a study of patient preference (par-
ticularly with respect to future childbearing) for the various
treatment strategies for uterine ﬁbroids represents an area for
future research.
Our study represents the ﬁrst cost-effectiveness analysis
to compare all of the major treatment options for women
with uterine ﬁbroids in the United States. Our ﬁndings sug-
gest that along with UAE and hysterectomy, use of MRgFUS
among premenopausal women with uterine ﬁbroids is within
therangeofcurrentlyacceptedcriteriaforcost-effectiveness.
Until more data on the long-term efﬁcacy of treatment op-
tions become available, any of the three could be the cost-
effective choice, depending on patient preferences and re-
source availability. Although myomectomy was not found to
be cost-effective in our analysis, it will remain an option for
womenplanningfuturepregnancyuntiladditionalsafetydata
on other uterine-sparing treatment strategies become avail-
able. Future cost-effectiveness studies would beneﬁt from
long-term studies that assess rates of recurrence and retreat-
ment over time, as well as preferences for and quality-of-life
impacts of the various treatments for uterine ﬁbroids.
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